NO20081379L - Pankreatinmikropelletkjerner egnet for enterisk belegning - Google Patents

Pankreatinmikropelletkjerner egnet for enterisk belegning

Info

Publication number
NO20081379L
NO20081379L NO20081379A NO20081379A NO20081379L NO 20081379 L NO20081379 L NO 20081379L NO 20081379 A NO20081379 A NO 20081379A NO 20081379 A NO20081379 A NO 20081379A NO 20081379 L NO20081379 L NO 20081379L
Authority
NO
Norway
Prior art keywords
pancreatin
enteric coating
pancreatin micropellet
cores suitable
micropellet cores
Prior art date
Application number
NO20081379A
Other languages
English (en)
Norwegian (no)
Inventor
Claus-Juergen Koelln
George Shlieout
Frithjof Sczesny
Jens Onken
Guido Ruesing
Original Assignee
Abbott Lab Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081379(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab Gmbh filed Critical Abbott Lab Gmbh
Publication of NO20081379L publication Critical patent/NO20081379L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
NO20081379A 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning NO20081379L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (1)

Publication Number Publication Date
NO20081379L true NO20081379L (no) 2008-05-14

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081379A NO20081379L (no) 2005-08-15 2008-03-14 Pankreatinmikropelletkjerner egnet for enterisk belegning

Country Status (15)

Country Link
EP (1) EP1931317B1 (de)
JP (1) JP5284092B2 (de)
KR (1) KR101302841B1 (de)
AT (1) ATE418329T1 (de)
AU (1) AU2006281415B2 (de)
CA (1) CA2619477C (de)
DE (1) DE602006004471D1 (de)
ES (1) ES2320174T3 (de)
IL (1) IL189457A (de)
MX (1) MX2008001557A (de)
NO (1) NO20081379L (de)
PL (1) PL1931317T3 (de)
PT (1) PT1931317E (de)
RU (1) RU2408364C2 (de)
WO (1) WO2007020260A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
BRPI0906439A2 (pt) * 2008-01-03 2018-12-04 Abbott Products Gmbh composições farmacêuticas que compreendem grânulos de lipase microbiana purificada e métodos para a prevenção ou tratamento de distúrbios digestivos
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2440210A4 (de) 2009-06-12 2014-01-29 Meritage Pharma Inc Verfahren zur behandlung von magen-darm-erkrankungen
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3639846B1 (de) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Verdauungsenzymzusammensetzung zur enteralen verabreichung
EP3157568A1 (de) 2014-06-19 2017-04-26 Aptalis Pharma Limited Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
CN114917328B (zh) 2014-11-05 2025-06-20 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
MX2022014395A (es) * 2020-06-10 2022-12-02 Kusum Healthcare Pvt Ltd Composicion farmaceutica de pancreatina.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102950325B1 (ko) 2024-01-26 2026-04-08 황준영 판크레아틴 함유 속방성 장용코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
BR0009012A (pt) * 1999-03-17 2001-12-26 Solvay Pharm Gmbh Medicamento para o tratamento de diabete
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
WO2007020260A3 (en) 2007-05-10
AU2006281415A1 (en) 2007-02-22
DE602006004471D1 (de) 2009-02-05
RU2008109651A (ru) 2009-09-27
AU2006281415B2 (en) 2012-01-19
ES2320174T3 (es) 2009-05-19
PL1931317T3 (pl) 2009-06-30
IL189457A0 (en) 2008-06-05
EP1931317A2 (de) 2008-06-18
PT1931317E (pt) 2009-02-02
MX2008001557A (es) 2008-02-15
CA2619477A1 (en) 2007-02-22
KR20080034516A (ko) 2008-04-21
EP1931317B1 (de) 2008-12-24
KR101302841B1 (ko) 2013-09-02
JP2009504710A (ja) 2009-02-05
HK1119559A1 (en) 2009-03-13
RU2408364C2 (ru) 2011-01-10
JP5284092B2 (ja) 2013-09-11
IL189457A (en) 2014-05-28
WO2007020260A2 (en) 2007-02-22
ATE418329T1 (de) 2009-01-15
CA2619477C (en) 2015-05-26

Similar Documents

Publication Publication Date Title
MX2008001557A (es) Nucleos de microglobulos de pancreativa adecuados para revestimiento enterico.
WO2010014949A3 (en) Compositions comprising hepatocyte-like cells and uses thereof
NO20084893L (no) Lyofiliserte terapeutiske peptistoffpreparater
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
WO2009055306A3 (en) Coating designs for the tailored release of dual drugs from polymeric coatings
WO2016061464A8 (en) In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
NO20090968L (no) Fremgangsmater for a behandle multippel myeloma ved anvendelse av kombinasjonsterapier basert pa anti-CS1 antistoffer
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
WO2016065323A3 (en) Single domain antibodies directed against intracellular antigens
TW200602089A (en) Sugar coatings and methods therefor
WO2011156602A3 (en) Method, system, and composition for coloring zirconia dental ceramics
MX2009010534A (es) Tecnologia de plataforma farmaceutica para el desarollo de productos naturales.
IL161903A0 (en) Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
EP1832275A3 (de) Hair-Styling-Zusammensetzungen mit einem Silikon-Elastomer und einem nichtwässrigen, polaren Lösungsmittel
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2011035062A3 (en) Spray dried human plasma
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
DK2151235T3 (da) Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
WO2008145842A3 (fr) Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
WO2009067543A3 (en) Treatment of histone deacetylase mediated disorders
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
MX2009003568A (es) Composicion para estilizado del cabello.
EP3735587A4 (de) Synchronisierter zellzyklus-genexpressionstest für morbus alzheimer und verwandte therapeutische verfahren
WO2009132119A3 (en) Substituted oxazolidinones

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT LABORATORIES GMBH, DE